Effect of neoadjuvant chemoradiotherapy on p53 and SOX2 protein expression in esophageal adenocarcinoma

被引：2
|
作者：
Suzuki, Lucia [1 ]
Nieboer, Daan [2 ]
van Lanschot, Jan J. B. [3 ]
Spaander, Manon C. W. [4 ]
Looijenga, Leendert H. J. [1 ,5 ]
Biermann, Katharina [1 ,6 ]
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Pathol, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr Rotterdam, Dept Surg, Rotterdam, Netherlands
[4] Erasmus MC Univ Med Ctr Rotterdam, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands
[5] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[6] MVZ Histol Zytol & Mol Diagnost Duren GmbH, Dept Pathol, Inst Pathol, Duren, Germany
来源：
BIOMARKERS IN MEDICINE | 2020年 / 14卷 / 09期
关键词：
biomarkers; esophageal adenocarcinoma; esophageal neoplasms; neoadjuvant therapy SOX2 protein; tumor suppressor protein p53; ADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMORADIOTHERAPY; CHEMORADIATION; SURVIVAL; CANCER; IMPACT;
D O I：
10.2217/bmm-2020-0135
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Aim: To determine if neoadjuvant chemoradiotherapy (nCRT) affects p53 and SOX2 expression in esophageal adenocarcinoma (EAC). Materials & methods: Comparison of p53 and SOX2 expression in 100 paired pre- and post-nCRT EAC samples. Results: Aberrant p53 was largely concordant (75/83, 90%), while 13/18 (72%) pre-nCRT samples with wild-type (WT) p53 staining, showed aberrant staining in paired post-nCRT samples. Similarly, 31/45 (69%) with previous WT SOX2 showed SOX2 loss in paired post-nCRT samples, whereas aberrant SOX2 loss was concordant in 50/55 (91%) cases. The prognostic values of both markers regarding survival differ before and after nCRT. Conclusion: Aberrant expression of p53 and SOX2 staining in EAC tissue is unaffected by nCRT. Conversely, the WT-staining pattern frequently changed to aberrant expression.
引用
收藏
页码：785 / 793
页数：9
相关论文
共 50 条
  • [1] P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy
    van Olphen, Sophie H.
    Biermann, Katharina
    Shapiro, Joel
    Wijnhoven, Bas P. L.
    Toxopeus, Eelke L. A.
    van der Gaast, Ate
    Stoop, Hans A.
    van Lanschot, Jan J. B.
    Spaander, Manon C. W.
    Bruno, Marco J.
    Looijenga, Leendert H. J.
    [J]. ANNALS OF SURGERY, 2017, 265 (02) : 347 - 355
  • [2] SOX2 and p53 Protein Expression Predicts Response to Preoperative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
    van Olphen, Sophie H.
    Biermann, Katharina
    Wijnhoven, Bas P.
    Spaander, Manon C.
    van der Gaast, Ate
    Lanschot, Jan J.
    Looijenga, Leendert
    Bruno, Marco J.
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S357 - S357
  • [3] Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma
    Ten Kate, Fiebo J. C.
    Suzuki, Lucia
    Dorssers, Lambert C. J.
    Dinjens, Winand N. M.
    Jones, David T. W.
    Nieboer, Daan
    Doukas, Michael
    Van Lanschot, J. Jan B.
    Wijnhoven, Bas P. L.
    Looijenga, Leendert H. J.
    Biermann, Katharina
    [J]. ONCOTARGET, 2017, 8 (61) : 104123 - 104135
  • [4] PROGNOSTIC VALUE OF P53 PROTEIN IN ESOPHAGEAL ADENOCARCINOMA
    CASSON, AG
    KERKVLIET, N
    OMALLEY, F
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1995, 60 (01) : 5 - 11
  • [5] P53 PROTEIN EXPRESSION IN ADENOCARCINOMA OF THE PROSTATE
    HUGHES, J
    ROBINSON, RA
    [J]. LABORATORY INVESTIGATION, 1994, 70 (01) : A76 - A76
  • [6] MDM2, p53 and pRb Expression Prior to Definitive Chemoradiotherapy in Esophageal Carcinoma
    Yoon, Mee Sun
    Nam, Taek Keun
    Lee, Jae Hyuk
    Cho, Sang Hee
    Song, Ju Young
    Ahn, Sung Ja
    Chung, Ik Joo
    Chung, Woong Ki
    Nah, Byung Sik
    [J]. RADIATION ONCOLOGY JOURNAL, 2007, 25 (04): : 193 - 200
  • [7] CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy
    Honing, Judith
    Pavlov, Kirill V.
    Mul, Veronique E. M.
    Karrenbeld, Arend
    Meijer, Coby
    Faiz, Zohra
    Smit, Justin K.
    Hospers, Geke A. P.
    Burgerhof, Johannes G. M.
    Kruyt, Frank A. E.
    Kleibeuker, Jan H.
    Plukker, John T. M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 117 (01) : 152 - 158
  • [8] THE EFFECT OF P53 PROTEIN OVER-EXPRESSION AND CLINICAL FEATURES ON THE RESPONSE TO PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA
    Anvari, K.
    Toosi, M. S.
    Nasiri, M. R. G.
    Gharfarzadegan, K.
    Pakdel, A. F.
    Salek, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 171 - 171
  • [9] MDM2/p53 protein expression in the development of colorectal adenocarcinoma
    Abdel-Fattah, G
    Yoffe, B
    Krishnan, B
    Khaoustov, V
    Itani, K
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2000, 4 (01) : 109 - 114
  • [10] MDM2/p53 protein expression in the development of colorectal adenocarcinoma
    Ghada Abdel-Fattah
    Boris Yoffe
    Bhuvaneswari Krishnan
    Vladimir Khaoustov
    Kamal Ltani
    [J]. Journal of Gastrointestinal Surgery, 2000, 4 : 109 - 114
12345